Date Insider Type Main position Quantity % Market Cap. Importance
7/7/20 Other

Director

30,000 0.8843%
7/7/20 Other

Director

30,000 0.8843%
7/7/20
Therapeutics Acquisition Holdings LLC
OtherCompany 2,785,000 82.0929%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-7.03% - - 175M
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+2.26%+5.51%+34.40%+29.18% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +0.87%-0.14%+54.20%+128.30% 43.39B
Weighted average by Cap. +1.57%-0.41%+58.29%+137.29%
Logo THES ACQU
POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).
Employees
-
  1. Stock Market
  2. Stocks
  3. RACA Stock